As you know, you are employed by XOMA Corporation (the “Company”) pursuant to the terms of an Officer Employment Agreement dated August 7, 2017, as amended on April 1, 2022 (the “Agreement”). You and the Company are hereby agreeing to amend the...Officer Employment Agreement • March 8th, 2024 • XOMA Corp • Pharmaceutical preparations
This Amendment forms the complete and exclusive agreement between you and the Company with respect to this subject matter. It supersedes any other agreements or promises made to you by anyone, whether oral or written, with respect to such subject matter. Changes to the terms of this Amendment require a written modification signed by an officer of the Company. This Amendment may be delivered and executed via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and shall be deemed to have been duly and validly delivered and executed and be valid and effective for all purposes.
AMENDED AND RESTATED OFFICER EMPLOYMENT AGREEMENTOfficer Employment Agreement • March 8th, 2024 • XOMA Corp • Pharmaceutical preparations • California
This Amended and Restated Officer Employment Agreement (“Agreement”) between Owen Hughes (“Employee”) and XOMA Corporation (“XOMA” or “the Company”) (collectively, the “Parties”) is effective as of January 8, 2024 (the “Agreement Effective Date”).
SALE, CONTRIBUTION AND SERVICING AGREEMENT dated as of December 15, 2023 between XOMA (US) LLC, as Seller, and Solely for purposes of Section 2.03 and Section 4.03(b)(ii), XOMA CORPORATION, as Parent, on the one hand and XRL 1 LLC, as Purchaser, on...Sale, Contribution and Servicing Agreement • March 8th, 2024 • XOMA Corp • Pharmaceutical preparations • New York
This SALE, CONTRIBUTION AND SERVICING AGREEMENT (this “Agreement”), dated as of December 15, 2023, is entered between XOMA (US) LLC, a Delaware limited liability company (“Seller”), and solely for purposes of Section 2.03 and Section 4.03(b)(ii), XOMA Corporation., a Delaware corporation (“Parent”), on the one hand; and XRL 1 LLC, a Delaware limited liability company (“Purchaser”), on the other hand.
ContractLoan Agreement • March 8th, 2024 • XOMA Corp • Pharmaceutical preparations
THE FOLLOWING INFORMATION IS SUPPLIED SOLELY FOR U.S. FEDERAL INCOME TAX PURPOSES. THE LOAN UNDER THIS AGREEMENT ARE TREATED AS HAVING BEEN ISSUED WITH ORIGINAL ISSUE DISCOUNT (“OID”) WITHIN THE MEANING OF SECTION 1273 OF THE INTERNAL REVENUE CODE OF 1986, AS AMENDED (THE “CODE”), AND THIS LEGEND IS REQUIRED BY SECTION 1275(c) OF THE CODE. INFORMATION INCLUDING THE ISSUE PRICE, THE AMOUNT OF ORIGINAL ISSUE DISCOUNT, THE ISSUE DATE AND THE YIELD TO MATURITY WILL BE PROVIDED IN WRITING TO A LENDER PROMPTLY UPON REQUEST TO THE BORROWER AT 2200 POWELL STREET, SUITE 310 EMERYVILLE, CA 94608 [***].
SECOND AMENDMENT TO OFFICE LEASEOffice Lease • March 8th, 2024 • XOMA Corp • Pharmaceutical preparations
This SECOND AMENDMENT TO OFFICE LEASE (this “Amendment”), dated as of June 27, 2023 (the “Effective Date”), is entered into by and between KBSIII TOWERS AT EMERYVILLE, LLC, a Delaware limited liability company (“Landlord”), and XOMA (US) LLC, a Delaware limited liability company (“Tenant”).
